Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT(TM) Glioblastoma Trial

GlobeNewswire June 16, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

GlobeNewswire June 10, 2021

Plus Therapeutics to Participate in BIO Digital Conference

GlobeNewswire June 9, 2021

Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

GlobeNewswire April 22, 2021

Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

GlobeNewswire April 8, 2021

Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

GlobeNewswire March 23, 2021

Plus Therapeutics to Participate in Upcoming Virtual Conferences

GlobeNewswire March 18, 2021

Plus Therapeutics to Participate in Upcoming Virtual Conferences

GlobeNewswire March 3, 2021

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

GlobeNewswire February 22, 2021

Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021

GlobeNewswire February 11, 2021

Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference

GlobeNewswire February 11, 2021

Plus Therapeutics to Participate in Upcoming January Conferences

GlobeNewswire January 5, 2021

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT(TM) Glioblastoma Trial

GlobeNewswire December 15, 2020

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference

GlobeNewswire December 8, 2020

Plus Therapeutics Expands ReSPECT(TM) Clinical Trial to MD Anderson Cancer Center

GlobeNewswire December 1, 2020

Plus Therapeutics Announces Positive Interim Data from ReSPECT(TM) Phase 1 Clinical Trial in Recurrent Glioblastoma

GlobeNewswire November 19, 2020

Plus Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire November 16, 2020

Plus Therapeutics Announces Webinar to Present ReSPECT(TM) Glioblastoma Clinical Trial Update

GlobeNewswire November 13, 2020

Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th

Accesswire November 12, 2020

Plus Therapeutics Announces Formation of Scientific Advisory Board

GlobeNewswire November 5, 2020